Navigation Links
Peloton Therapeutics Completes $18 Million Series A Financing

DALLAS, July 27, 2011 /PRNewswire/ -- Peloton Therapeutics, Inc., an early-stage cancer drug discovery and development company, has announced the completion of an $18 million Series A financing.  Led by The Column Group and joined by Remeditex Ventures and Peter O'Donnell, Jr., the Series A funds supplement a recently awarded $11 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

Peloton officials said the company will focus initially on advancing several well differentiated oncology programs, each of which has already yielded promising lead compounds with novel mechanisms of action. Peloton leveraged its close relationship with the University of Texas Southwestern Medical Center to in-license these programs, providing a kick-start to its internal research and development capabilities. Peloton's goal is to become a leading oncology company generating a sustainable pipeline of cancer therapies that are designed to enhance outcomes and treatment practices.  

The Company was founded by renowned scientist Steven L. McKnight, Ph.D., who is recognized as one of the world leaders in gene regulation based in part on his discovery of leucine zipper proteins. Dr. McKnight is Chairman of Biochemistry at UT Southwestern and holds the Distinguished Chair in Basic Biomedical Research and the Sam G. Winstead and F. Andrew Bell Distinguished Chair in Biochemistry. The high-throughput screening laboratory Dr. McKnight built at the medical center over the past decade has seeded the Peloton pipeline with a number of attractive compounds that are well positioned for lead optimization.

"Peloton has the potential to emerge as a top-notch cancer company, distinguished by its scientific rigor, drug discovery capabilities, and talented team," Dr. McKnight said. "Peloton is off to a strong start in advancing its therapeutic programs quickly and effectively."

Peloton's Board of Directors includes Nobel Laureate Michael S. Brown, M.D., Regental Professor of the University of Texas System and Director of UT Southwestern's Erik Jonsson Center for Research in Molecular Genetics and Human Disease; John W. Creecy, CEO, Remeditex Ventures; David V. Goeddel, Ph.D., Managing Partner, The Column Group; Tim Kutzkey, Ph.D., Partner, The Column Group; and Brett A. Ringle, President, Remeditex Ventures.  John A. Josey, Ph.D., former Vice President of Discovery Chemistry at Array BioPharma, Inc., will join Peloton as President and Chief Scientific Officer.

"Peloton's respected leadership team and focus on cutting-edge cancer biology, as well as its relationships with UT Southwestern and CPRIT, make it an attractive investment opportunity with significant value-creation potential. We are pleased to support the Company's ability to pursue its discovery and development goals," said David V. Goeddel, Ph.D., Managing Partner, The Column Group.

CPRIT ( focuses on expediting the innovation and commercialization of cancer research – in turn increasing the potential for a medical or scientific breakthrough – and enhancing access to evidence-based prevention programs and services. CPRIT accepts applications from Texas-based public and private entities for grants to support a wide variety of cancer-related research projects and for the delivery of cancer prevention programs and services.

"Peloton is an emblem of the emerging Texas-based biotechnology community, and CPRIT is delighted to contribute to its potential success in developing breakthrough cancer therapeutics and delivering significant value to cancer patients and their families. We anticipate a long and productive collaborative relationship," said Jerry Cobbs, CPRIT's Chief Commercialization Officer.

About Peloton

A peloton is a team of bicyclists who achieve great efficiency of motion through cooperative action.  It is also the root of platoon, a nimble military unit with capabilities that exceed the sum of its component parts.  Founded by Chairman of Biochemistry Steven L. McKnight of UT Southwestern Medical Center, Peloton Therapeutics represents a unique combination of innovative science, strong financial support from the Cancer Prevention Research Institute of Texas (CPRIT), and seasoned investors and management.  Working in close collaboration with scientists at UT Southwestern, Peloton is advancing a promising discovery and development pipeline, comprised of several small molecule-based programs, each with a distinct target and mechanism of action.  Peloton's vision is to become a major biotech company in Dallas with a passion for discovering and developing novel cancer drugs. For more information, please visit

About UT Southwestern Medical Center

One of the premier academic medical centers in the nation, UT Southwestern integrates pioneering biomedical research with exceptional clinical care and education. UT Southwestern physicians provide care to more than 100,000 hospitalized patients and oversee nearly 2 million outpatient visits a year. Its three degree-granting institutions train nearly 4,400 students, residents and fellows each year, and its researchers undertake more than 3,500 research projects annually, totaling almost $417 million in federal, state and private support. For information, visit


Jane Green, for Peloton Therapeutics
415.348.0010 phone
415.652.4819 cell

SOURCE Peloton Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
2. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
3. Oxygen Healthcare (O2h) Announces Expanded Chemistry Collaboration With Heptares Therapeutics
4. Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis therapeutics
5. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
6. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
7. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
8. Sorrento Therapeutics Innovative Approach to Developing Vaccines and Therapeutics for MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases
9. Amicus Therapeutics Joins Russell 3000® Index
10. Nile Therapeutics Provides Update on Ongoing Phase I Clinical Trial of Cenderitide
11. Nile Therapeutics, Inc. Completes $2.5 Million Private Placement
Post Your Comments:
(Date:10/8/2015)... Celemics, a global pioneer of personalized medicine ... market with the establishment of Celemics America, Inc. ... Europe , has secured itself in the global ... sample preparation for DNA sequencing and genetic testing.  Next ... genetic testing more accurately, quickly, and cost effectively than ...
(Date:10/8/2015)... 8, 2015  The ALS Association, in partnership with ... Challenge to revolutionize communication technology solutions for people living ... ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative ... and the spinal cord. Eventually, people with ALS lose ... often leads to total paralysis and death within two ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS ... license agreement to develop and commercialize intellectual property rights belonging to The University ... February 2009, and affords exclusive worldwide rights to intellectual property based on use ...
(Date:10/7/2015)... Dallas-Fort Worth, Texas (PRWEB) , ... October 07, ... ... Stem Cell Institute ( ) will present a public educational seminar on ... diseases on Saturday, October 10th from 1:00 pm – 3:00 pm at the ...
Breaking Biology Technology:
... Nov. 28 On Monday, December 1, 2008, at,8:30 ... Therapeutics, Inc.,s (CTI) (Nasdaq and MTA: CTIC) management team ... Spectrum Pharmaceuticals,of Irvine, California to jointly market and develop ... Call Numbers, Monday, December 1, ...
... today that it is refocusing all projects and priorities around ... be seen as a,consequence of the negative recommendation of the ... 2008 regarding the,approval of Iclaprim in the U.S. , ... FDA advisory board,s recommendation the Arpida,board intends to put the ...
... house always looking good, without cleaning or giving it ... with paint that can maintain itself and get rid ... process for producing photo-catalytic, self-cleaning coatings has been developed ... and Research), and licensed to Haruna (S) Pte Ltd. ...
Cached Biology Technology:
(Date:9/24/2015)... YORK , Sept. 24, 2015  EyeLock LLC, ... be showcasing its award winning and latest technology in ... Anaheim, California . EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:9/10/2015)... 10, 2015 Report Details ... Selling Opportunities and Revenue Prospects to Help You ... biologics, especially new drug classes? Get the latest ... with exclusive market data and industry knowledge, benefitting ... results, opportunities and sales predictions. Visiongain,s new ...
(Date:9/10/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces that the San ... will feature the Wocket® smart wallet for the first ... Touch Of Modern is an online retailer ... its 7.2 million members. Customers are affluent, urban influencers ...
Breaking Biology News(10 mins):
... and their colleagues in Japan are conducting research that may ... necessary step if man someday hopes to build molecular machines ... Dr. Eric Blough, a member of the research ... Biological Sciences, said his group has shown how bionanomotors can ...
... Biologists have known for long that ecology, the interaction ... in forming new species and in modifying living ones. ... The environment defines a template and the process of ... template. Some specialized theory, a few ...
... plant virus lures aphids to infected plants by making the ... they quickly leave for tastier, healthier ones. In the process, ... entomologists. "The virus improves the cues that insects use to ... is already in the plant," said Mark C. Mescher, assistant ...
Cached Biology News: